Centessa Pharmaceuticals Limited (CNTA) News

Centessa Pharmaceuticals Limited (CNTA): $18.90

0.11 (+0.59%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter CNTA News Items

CNTA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CNTA News Highlights

  • CNTA's 30 day story count now stands at 8.
  • Over the past 8 days, the trend for CNTA's stories per day has been choppy and unclear. It has oscillated between 2 and 6.
  • The most mentioned tickers in articles about CNTA are ABR, GEVO and MG.

Latest CNTA News From Around the Web

Below are the latest news stories about Centessa Pharmaceuticals plc that investors may wish to consider to help them evaluate CNTA as an investment opportunity.

Heres why Centessa Pharma is up 20% on Thursday morning

Centessa Pharmaceuticals PLC ADR (NASDAQ: CNTA), in partnership with its subsidiary ApcinteX Limited announced that results from its ongoing first-in-human proof-of-concept study to analyze SerpinPC in severe hemophilia A and B patients are positive. This news automatically pushed the Pharma stock up by 20% on Thursday morning. The study demonstrates that SerpinPC is well-tolerated [] The post Heres why Centessa Pharma is up 20% on Thursday morning appeared first on Invezz .

Invezz | September 9, 2021

Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis

~ 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~ ~ SerpinPC observed to be well-tolerated ~ ~ Company has initiated planning for global registrational program ~ ~ Conference call and webcast scheduled for today at 8:30 a.m. EDT ~ CAMBRIDGE, Mass. and LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc ("Company") (NASDAQ: CNTA ), together with subsidiary ApcinteX Limited ("ApcinteX"), today announced positive topline results from the Phase 2a part of AP-0101, the six-month repeat dose portion of its ongoing first-in-human proof-of-concept study evaluating SerpinPC in severe hemophilia A and B patients. AP-0101 is a Phase 1/2a proof-of-concept study evaluating ...

Benzinga | September 9, 2021

Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis

~ 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~ ~ SerpinPC observed to be well-tolerate

FinanzNachrichten | September 9, 2021

Centessa Stock Surges On Positive Data From Hemophilia Candidate

Centessa Pharmaceuticals plc (NASDAQ: CNTA ) has announced positive topline results from the Phase 2a part of

Business Insider Markets | September 9, 2021

35 Stocks Moving In Thursday's Mid-Day Session

Gainers Gevo, Inc. (NASDAQ: GEVO) shares climbed 36.6% to $7.91. Chevron and Gevo announced intent to pursue sustainable aviation fuel investment. Offerpad Solutions Inc (NYSE: OPAD) surged 35.3% to $15.62. Torrid Holdings Inc. (NYSE: CURV) shares gained 26.1% to $23.29 after the company reported better-than-expected Q2 EPS and sales results. Torrid sees Q3 sales of $305 million - $315 million, above the consensus of $294.74 million. The company expects FY21 sales of $1.29 billion - $1.31 billio

Yahoo | September 9, 2021

Centessa Pharmaceuticals plc: Centessa Pharmaceuticals to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference

CAMBRIDGE, Mass. & LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate i

FinanzNachrichten | September 1, 2021

Centessa Pharmaceuticals to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference

CAMBRIDGE, Mass. & LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an analyst-led fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021, beginning at 5:00 p.m. Eastern Time. A live audio webcast of this event can be accessed on the investor relations section of the Centessa Pharmaceuticals website at http

Yahoo | September 1, 2021

Centessa Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Updates

~ Successful completion of an initial public offering of American Depositary Shares raising gross proceeds of $379.5 million to help advance portfolio of 16 clinical and preclinical programs ~

Intrado Digital Media | August 16, 2021

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street

Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK ) ( announced topline results from Cohorts 1 and 2 of the Phase 2 study of CK-274 in obstructive outflow disease in hypertrophic cardiomyopathy) Forward Pharma A/S (NASDAQ: FWP ) ResMed Inc. (NYSE: NRMD) Legend Biotech Corporation (NASDAQ: LEGN ) Moderna, Inc. (NASDAQ: MRNA ) ( extended gains on recent momentum) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 19) 4D pharma plc (NASDAQ: LBPS ) Adaptimmune Therapeutics plc (NASDAQ: ADAP ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Allena P...

Benzinga | July 20, 2021

Goldman Sachs Sees These 3 Stocks Skyrocketing Over 60%

The S&P 500 has been rising all year, and to date has posted gains of more than 16%. After a more volatile start to the year, with strong swings up and down from January to the end of May, during which investors pulled back from the tech giants, the NASDAQ has joined the upward trend. Its year-to-date gain now stands at 14%, and like the S&P, sits just under a record high level. But how much room is there for further growth across the board? In an environment like this, investors need to take care.

Michael Marcus on TipRanks | July 14, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7176 seconds.